Clinical Value of Tumor Markers for Early Detection of Recurrence in Patients with Cervical Adenocarcinoma and Adenosquamous Carcinoma

Abstract

Objective: The clinical value of tumor markers for early detection of recurrence was investigated in 32 patients with cervical adenocarcinoma or adenosquamous carcinoma who had recurrent tumors. Methods: Serum levels of CA 125, CA 19-9, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC), in addition to clinical status at the time of recurrence were investigated. Results: Among the 32 patients, 26 had no symptoms at the time of recurrence. In 20 patients, elevated serum levels of tumor markers were the first sign of recurrence. In 21 patients with recurrent adenocarcinoma, the positive rates were 14% (CA 125), 62% (CA 19-9), 29% (CEA), and 5% (SCC). There were 71% of cases positive for CA 19-9 and/or CEA. In 11 patients with recurrent adenosquamous carcinoma, the corresponding positive rates were 37% (CA 125), 46% (CA 19-9), 64% (CEA), and 55% (SCC), with 100% positive for CA 19-9, CEA, and/or SCC. Conclusions: The combination of CA 19-9 and CEA is probably the most promising for detection of recurrent cervical adenocarcinoma. For adenosquamous carcinoma, the additional use of SCC is recommended.

Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers

“…The purpose of the new markers is primarily to reduce the percentage of undiagnosed patients, which will also improve their survival rate. Cytological screening proves successful for squamous lesions [2, 80] however this method is not effective in diagnostics of cervical adenocarcinoma yet [40]. Moreover, the cervical adenocarcinoma seems to be aggressive, and more often, lymph nodes metastases are observed in these patients [1].…”

The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature

“…In the series of Leminen [88], CA 125 and CEA levels increased in 71 and 36%, respectively, of cervical adenocarcinoma patients who developed progressive disease. Tabata et al [91] detected elevated levels of CA 125, CA 19-9, CEA, CA 19-9 and/or CEA in 14, 62, 29 and 71% of 21 patients with recurrent adenocarcinoma and, respectively, in 37, 46, 64 and 100% of 11 patients with recurrent adeno-squamous carcinoma of the uterine cervix.…”

“…Among these latter, the logistic regression showed that pre-operative serum CA 125 > 26 U/ml was related to lymph-vascular space invasion (p = 0.04) and deep cervical stromal invasion (p = 0.002). Patients with cervical adenocarcinoma sometimes showed raised levels of 28,89,91] and CEA [33,85,86,88,89,91,92], first identified in tissue and serum samples from patients with colon cancer.…”

“…Rising serum CA 125 during follow-up may be coincident with or precede the clinical diagnosis of recurrent cervical adenocarcinoma [85,88,91,93]. Niloff et al [93] found serum CA 125 > 35 U/ml in all five patients with recurrent disease.…”

Standardowe i potencjalne markery nowotworowe u chorych na raka szyjki macicy

“…CEA może być także wytwarzany i uwalniany do krążenia u chorych na nowotwory o innych umiejscowieniach, między innymi w nowotworach narządu rodnego, żołądka, trzustki, piersi, płuca, pęcherza moczowego, gruczołu krokowego oraz w przerzutach do wątroby [6,[23][24][25]. W piśmiennictwie opisywany jest związek stężeń CEA z typem histopatologicznym raka, w rakach gruczołowych szyjki macicy podwyższone stężenia CEA obserwuje się częściej niż w płaskonabłonkowych [10,16,26]. [5,10,23,27].…”